Patient Power®
Get Email Alerts!
Health Topics
Chronic Myelogenous Leukemia (CML) Health Center
Health Center Home About Our CML Education Center About CML Living with CML Patient Stories Support and Resources News and Views Sign up for...
Search by Keyword:
Search by Health Topic:
View all Health Topics >
7/9/12

News from ASCO: Could Some Patients Stop Taking Medication for CML?

Jeffrey Lipton discusses news from ASCO 2012 about how Tasigna could bring faster and deeper responses, taking some newly diagnosed patients all the way to Complete Molecular Response (CMR) well within the first year of therapy. Dr. Lipton explains that the focus in Chronic Myelogenous Leukemia (CML) is moving away from simply keeping patients alive and toward the possibility of a cure and being able to discontinue treatment.

Get Email Updates:

Get updated automatically when new content about Chronic Myelogenous Leukemia has been posted.
Privacy Policy
Chronic Myelogenous Leukemia

Experts & Guests

Jeffrey Lipton Jeffrey Lipton,
MD, FRCPC, PhD
Dr. Jeffrey Lipton is the Head of the Chronic Myeloid Leukemia Program, Princess Margaret Hospital, Ontario Cancer Institute (OCI). He is a member of the Allogeneic Blood and Bone Marrow Transplant Program and the Clinical Studies Resource Centre at OCI. Dr. Lipton's research includes phase I, II and III levels on the therapy of chronic myeloid leukemia. This involves targeted... more >

Transcript

  1. Could Some Patients Stop Taking Medication for CML?

Related Programs

Dr. Jorge Cortes explains the latest news from ASCO on existing and emerging treatments for CML including updates on Ponatinib, Bosutinib and Omacetaxine.

Watch Now
Executive Director, Greg Stephens and Director of Patient Care Services, Alisa Peinhardt from the National CML Society, share their perspectives on the latest developments from ASCO 2012.

Watch Now
Dr. Tomasz Beer hopes that a new book will help patients feel more confident when discussing clinical trials as part of their treatment.

Watch Now